Compare REVB & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REVB | BRTX |
|---|---|---|
| Founded | 2020 | 1997 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Biotechnology: Pharmaceutical Preparations | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 3.7M |
| IPO Year | 2020 | 2015 |
| Metric | REVB | BRTX |
|---|---|---|
| Price | $0.98 | $2.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.1K | ★ 202.6K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.68 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $298.39 |
| Revenue Next Year | N/A | $64.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.47 | $0.14 |
| 52 Week High | $2.32 | $4.10 |
| Indicator | REVB | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.73 | N/A |
| Support Level | $0.96 | N/A |
| Resistance Level | $1.21 | N/A |
| Average True Range (ATR) | 0.04 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 69.23 | 0.00 |
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.